A Role for Lipid Mediators in Acute Myeloid Leukemia

Abstract

In spite of therapeutic improvements in the treatment of different hematologic malignancies, the prognosis of acute myeloid leukemia (AML) treated solely with conventional induction and consolidation chemotherapy remains poor, especially in association with high risk chromosomal or molecular aberrations. Recent discoveries describe the complex interaction of immune effector cells, as well as the role of the bone marrow microenvironment in the development, maintenance and progression of AML. Lipids, and in particular omega-3 as well as omega-6 polyunsaturated fatty acids (PUFAs) have been shown to play a vital role as signaling molecules of immune processes in numerous benign and malignant conditions. While the majority of research in cancer has been focused on the role of lipid mediators in solid tumors, some data are showing their involvement also in hematologic malignancies. There is a considerable amount of evidence that AML cells are targetable by innate and adaptive immune mechanisms, paving the way for immune therapy approaches in AML. In this article we review the current data showing the lipid mediator and lipidome patterns in AML and their potential links to immune mechanisms.

Lipidomic-Based Advances in Diagnosis and Modulation of Immune Response to Cancer

“…Besides directly mediating inflammation, PGE 2 might be used as an intermediate not only in the signaling between immune cells but also between immunity and tumors. Hence, PGE 2 released from DCs affects the generation and proliferation of Tregs by immunosuppressive cytokines like IL-10, whereas PGE 2 released from tumor cells is able to regulate DC maturation [ 37 , 38 , 39 ]. This COX2/PGE 2 pathway is also involved in the regulation of the immune checkpoint enzyme expression, like PD-L1, in tumor-infiltrating macrophages and other myeloid cells [ 40 ].…”

“…This makes fatty acids robust biomarker candidates. Recent studies have shown that genetic alterations observed in acute myeloid leukemia (AML) patients control lipid dynamics and metabolism [ 39 , 85 ]. Interestingly, patients with AML can be identified by specific lipid signatures in plasma [ 86 ] and bone marrow [ 87 ].…”

Drugging cancer metabolism: Expectations vs. reality

“…Lipids, which have historically been considered as mere structural components of cell membranes, are now widely considered as key nutrients and signal transducers that play a major role in oncogenic pathways (Hannun and Obeid, 2018;Loew et al, 2019;Wang et al, 2018).…”

Lipidomics Conquers a Niche, Consolidates Growth

“…Public health issues, cancer, and cardiovascular disease are the foci of three of the articles. Two of these reviews address the role of polyunsaturated-derived mediators in hematologic malignancies [13], and the last review is related to the involvement of lipid metabolism modifications in the pathogenesis of viral infection-induced cancers [14]. Solati and colls.…”